{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Corines MJ"],"funding":["National Institutes of Health National Cancer Institute","NCI NIH HHS","National Institutes of Health"],"pagination":["111986"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11892329"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["184"],"pubmed_abstract":["<h4>Background</h4>We explored the use of MRI T2-weighted imaging (T2WI) radiomics to help distinguish acellular mucin from cellular mucin (residual tumor) to inform patient management.<h4>Methods</h4>This retrospective, multi-institutional study included consecutive patients with rectal adenocarcinoma containing mucin on restaging MRI from March 2012-January 2020. Radiologists segmented 3-mm-thick T2WI. Data were split into training (n = 122), validation (n = 40), and test (n = 42) sets. Sensitivity, specificity, PPV, NPV, and AUC of the developed radiomic models were investigated on the test set. Histopathology was the reference standard. Two radiologists independently reviewed 42 patients using a unique five-point Likert scale for the probability of cellular mucin. DeLong-Delong or McNe"],"journal":["European journal of radiology"],"pubmed_title":["Can MRI radiomics distinguish residual adenocarcinoma from acellular mucin in treated rectal cancer?"],"pmcid":["PMC11892329"],"funding_grant_id":["P30 CA008748"],"pubmed_authors":["Lee S","Sheedy SP","Schwartz LH","Zhao B","Ibrahim A","Ernst R","Gollub MJ","Korngold E","Miranda J","Zheng J","Horvat N","Nougaret S","Moreno CC","Fox M","Nahas SC","Baheti A","Corines MJ","Gangai N","Petkovska I","Sosa RE","Gibbs P"],"additional_accession":[]},"is_claimable":false,"name":"Can MRI radiomics distinguish residual adenocarcinoma from acellular mucin in treated rectal cancer?","description":"<h4>Background</h4>We explored the use of MRI T2-weighted imaging (T2WI) radiomics to help distinguish acellular mucin from cellular mucin (residual tumor) to inform patient management.<h4>Methods</h4>This retrospective, multi-institutional study included consecutive patients with rectal adenocarcinoma containing mucin on restaging MRI from March 2012-January 2020. Radiologists segmented 3-mm-thick T2WI. Data were split into training (n = 122), validation (n = 40), and test (n = 42) sets. Sensitivity, specificity, PPV, NPV, and AUC of the developed radiomic models were investigated on the test set. Histopathology was the reference standard. Two radiologists independently reviewed 42 patients using a unique five-point Likert scale for the probability of cellular mucin. DeLong-Delong or McNe","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Mar","modification":"2026-07-16T23:39:03.802Z","creation":"2026-07-12T03:11:44.219Z"},"accession":"S-EPMC11892329","cross_references":{"pubmed":["39923594"],"doi":["10.1016/j.ejrad.2025.111986"]}}